Bioequivalence study drug containing memantine
Abstract
At present, Russia has developed domestic analogue of Memantine Akatinol — Memaneyrin in the form of droplets which is pharmaceutically equivalent drug memantine Akatinol. The aim of this study was to investigate the bioequivalence of the two formulations of memantine: Memaneyrin (drops, 10 mg) and Akatinol memantine (drops, 10 mg). Bioequivalence assessment was carried out by determining the concentration of memantine in plasma of volunteers, which was determined by HPLC with mass spectrometric detection.
About the Authors
A. A. Karlitskaya
FGBI «Scientific Center for Expertise of Medical Products», Moscow
Russian Federation
Russian Federation
L. M. Krasnyh
FGBI «Scientific Center for Expertise of Medical Products», Moscow
Russian Federation
Russian Federation
V. V. Smirnov
FGBI «Scientific Center for Expertise of Medical Products», Moscow; Medical University «First MGMU them I.M. Sechenov», Moscow
Russian Federation
Russian Federation
G. F. Vasilenko
FGBI «Scientific Center for Expertise of Medical Products», Moscow
Russian Federation
Russian Federation
N. I. Kuznetsova
Medical University «First MGMU them. IM Sechenov», Moscow
Russian Federation
Russian Federation
V. G. Kukes
FGBI «Scientific Center for Expertise of Medical Products», Moscow
Russian Federation
Russian Federation
References
1. Forette F., Hauw J.J. Alzheimer’s disease: from brain lesions to new drugs. // Bulletin de L’academie nationale de medicine. 2008. 192(2). P. 363—380.
2. Гаврилова С.И., Калын Я.Б., Селезнева Н.Д. и др. Глутаматергическая терапия болезни Альцгеймера на стадии умеренно-тяжёлой и тяжёлой деменции: результаты 26 недельного исследования эффективности и безопасности препарата Акатинол мемантин. // Неврология и психиатрия им. С.С. Корсакова. 2005. № 2. С. 72—76.
3. Reisberg B, Doody R., Stoffler A. et al. Memantine in moderate-to-severe Alzheimer’s disease. // N. Engl. J. Med. 2003. V. 348. P. 1333—1341.
4. Дамулин Н.В. Новая нерйропротекторная и терапевтическая стратегия при деменции: антагонист NMDA-рецептовор акатинол мемантин. // Рус. мед. журнал. 2001. 9(25). С. 1178—1182.
5. Marum van R.J. Update on the use of memantine in Alzheimer’s disease. // Neuropsychiatr. Dis. Treat. 2009. Vol. 5. P. 237—247.
6. Danysz W., Parsons C.G., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist — a review of preclinical data. // Neuropharmacology. 1999. Vol. 38. P. 735—767.
7. Subramaniam S., Sixt K.M., Barrow R. et al. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. // Science. 2009. Vol. 324. P. 1327—1330.
8. Федеральный закон №61-ФЗ от 12 апреля 2010 г. «Об обращении лекарственных средств».
9. Hassan M.G., Emara K.M. Mohamed H.A. et al. Determination of memantine in rat plasma by HPLC-fluorescence method and its application to study of the pharmacokinetic interaction between memantine and methazolamide. // Biomed. Chromatogr. 2011. Vol. 10. P. 1648.
10. Toker S.E., Sagirli O., Cetina S.M. et al. A new HPLC method with fluorescence detection for the determination of memantine in human plasma. // J. Sep. Sci. 2011. Vol. 19. P. 2645—2649.
11. Koeberle M.J., Hughes P.M., Wilson C.G. et al. Development of a liquid chromatography-mass spectrometric method for measuring the binding of memantine to different melanins. // J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 2003. Vol. 787(2). P. 313—322.
12. Leis H.J., Fauler G., Windischhofer W. Quantitative analysis of memantine in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry. // J. Mass. Spectrom. 2002. Vol. 37(5). P. 477—480.
13. Оценка биоэквивалентности лекарственных средств: Методические указания. М., 2008. 32 с.
Review
For citations:
Karlitskaya A.A., Krasnyh L.M., Smirnov V.V., Vasilenko G.F., Kuznetsova N.I., Kukes V.G. Bioequivalence study drug containing memantine. Pharmacokinetics and Pharmacodynamics. 2013;(2):18-24. (In Russ.)
Views:
873
Email this article 